Shares in Ophthotech (NSDQ:OPHT) dipped to $2.46 apiece this morning after the company announced that its Phase III wet age-related macular degeneration trial failed to meet its primary endpoint.
The New York-based company said that the addition of Fovista (pegpleranib) to Eylea or Avastin, both anti-VEGF therapies, did not significantly improve visual acuity after 12-months compared to Eylea or Avastin alone.
Get the full story at our sister site, Drug Delivery Business News.
The post Ophthotech eye-drug trial fails to meet primary endpoint appeared first on MassDevice.
from MassDevice http://ift.tt/2wIRsDh
Cap comentari:
Publica un comentari a l'entrada